VIRALEZE nasal spray. Source: Starpharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
  • The company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast Asia, and it’s now in discussions with potential distribution partners
  • The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets
  • Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries
  • Shares in Starpharma are up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT

Starpharma (SPL) has registered its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation.

Following the successful registration, the company is in discussions with potential distribution partners in Indonesia.

CEO Jackie Fairley said Indonesia represents an “exciting market opportunity” for the company as the country is the largest and most populous country in Southeast Asia.

“We have seen strong interest in VIRALEZE across Asia, including in Vietnam, and in Hong Kong and Macau where the product recently launched through major pharmacy chains, Mannings and Watsons, as well as selected supermarkets.”

The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets.

Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries, including in markets across Southeast Asia.

VIRALEZE is a nasal spray that is intended to physically trap, and block cold and respiratory viruses in the nasal cavity.

Multiple nonclinical studies have shown that VIRALEZE traps and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza viruses, rhinoviruses, and respiratory syncytial virus.

Shares in Starpharma were up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT.

SPL by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…